Noze is a technology company.
Noze has built the first platform to analyze breath chemistry with clinical precision, enabling earlier detection of diseases and better patient outcomes.
Noze has raised $10.0M across 1 funding round.
Noze has raised $10.0M in total across 1 funding round.
Noze is a Montreal-based medtech company building a semiconductor-scale “digital nose” and AI perception platform to analyze breath and other odor signatures for real‑time, non‑invasive diagnostics and monitoring across healthcare and adjacent industries.[4][2]
High‑Level Overview
Noze builds a nano‑sensor array plus an AI perception engine that converts trace molecular (VOC) patterns in breath into clinical signals, aiming for point‑of‑care devices that work outside the lab.[4][2]
Its primary customers are healthcare providers, clinical researchers and device partners (point‑of‑care clinical use cases such as infectious disease screening and cancer patient monitoring are emphasized), while the platform also has potential applications in consumer health, food quality and safety and public safety.[3][2]
The problem Noze addresses is slow, invasive or lab‑bound diagnostics: by detecting disease‑relevant volatile biomarkers in breath in real time, the company seeks to enable earlier screening, monitoring and treatment decisions without blood draws or centralized labs.[4][3]
Recent signals of growth and validation include peer‑reviewed studies and clinical collaborations referenced on its site, grant support (including a Bill & Melinda Gates Foundation grant for TB work reported in media), and venture backing from investors such as BDC Capital and others; the company reports multiple funding rounds and ~ $5M total disclosed funding in public profiles.[1][4][2]
Origin Story
Noze (formerly Stratucent) was founded around 2015 and is headquartered in Montreal; the company evolved from long R&D into a commercial diagnostic platform over more than a decade of sensor and AI work.[3][4]
Founders and core technical team are framed on the company site as scientists and engineers who translated biological olfaction concepts into a silicon nano‑sensor and neural perception stack; their sensor technology is described as developed using IP licensed from NASA‑related research and refined through clinical collaborations and publications.[4][2]
Early traction and pivotal moments include demonstration studies and peer‑reviewed validation, strategic grants (e.g., Gates Foundation support for tuberculosis work reported in press), and portfolio inclusion by investors such as BDC Capital that list Noze as a leading digital odor perception company.[1][2]
Core Differentiators
Role in the Broader Tech Landscape
Noze sits at the intersection of medtech sensors, edge AI and decentralized diagnostics—trends accelerating because of demand for rapid, low‑cost, point‑of‑care testing and greater emphasis on non‑invasive monitoring.[4][3]
Timing matters: advances in nano‑fabrication, AI model development, and growing clinical acceptance of digital biomarkers lower technical and regulatory barriers for breath‑based diagnostics now versus a decade ago.[4][2]
Market forces in its favor include global needs for scalable infectious disease screening (notably in low‑resource settings), oncology care models shifting toward outpatient monitoring, and health systems seeking to reduce lab burden and costs.[1][3]
If successful, Noze could influence the ecosystem by validating odor‑based biomarkers as clinically actionable, catalyzing new device categories and partnerships between semiconductor manufacturers, AI firms and healthcare providers.[4][2]
Quick Take & Future Outlook
Near term, expect continued clinical validation, regulatory pathway work, and targeted pilots for high‑impact use cases such as TB screening and cancer‑therapy monitoring (e.g., neutropenia risk), supported by grants and strategic partnerships.[1][3][4]
Medium term, scaling will hinge on demonstrating consistent clinical performance across populations, obtaining regulatory clearances, and leveraging semiconductor manufacturing to lower unit cost and enable widespread deployment.[4]
Longer term, if Noze converges reliable sensor hardware, robust AI models, and compliant clinical workflows, it could become a foundational platform for non‑invasive diagnostics and remote monitoring—shifting parts of diagnostic volume from centralized labs to distributed clinical and consumer settings.[4][2]
Quick take: Noze is a well‑capitalized, Montreal‑based leader in digital odor perception focused on turning breath chemistry into real‑time clinical intelligence; its success will depend on continuing clinical validation, regulatory progress, and execution at scale using its “smell on silicon” approach.[4][2]
Noze has raised $10.0M in total across 1 funding round.
Noze's investors include BDC Venture Capital, Chrysalix Venture Capital, Prelude Ventures.
Noze has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in March 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2022 | $10.0M Series A | BDC Venture Capital, Chrysalix Venture Capital, Prelude Ventures |